This inventor holds 3 USPTO granted patents and 5 published patent applications. Top assignees: Ludwig Institute for Cancer Research Limited, Université De Lausanne, Chuv—centre Hospitalier Universitaire Vaudois. Active years: 2023-2025.
Company Filing History:
2 out of 530 
2 out of 26 
1 out of 1 Years Active: 2023-2025
Title: Melita Irving: Innovator in Kinase Mutants
Introduction
Melita Irving is a prominent inventor based in Prilly, Switzerland. She has made significant contributions to the field of biotechnology, particularly in the design and application of kinase mutants. Her work focuses on enhancing the sensitivity of target kinases to specific inhibitors, which has important implications for cancer treatment.
Latest Patents
Melita Irving holds a patent titled "Kinase mutants and uses thereof." This invention relates to methods for designing kinase mutants that can be reprogrammed to respond to specific inhibitors. These inhibitors have little or no affinity for the wild-type target kinase. The patent also covers vectors or cells expressing these mutated kinases, along with compositions and uses for the prevention and treatment of diseases, particularly cancer.
Career Highlights
Throughout her career, Melita has worked with esteemed organizations such as the Swiss Institute of Bioinformatics and the Centre Hospitalier Universitaire Vaudois. Her experience in these institutions has allowed her to advance her research and contribute to significant scientific advancements.
Collaborations
Melita has collaborated with notable colleagues, including Olivier Michielin and Vincent Zoete. These partnerships have fostered innovation and have been instrumental in her research endeavors.
Conclusion
Melita Irving is a trailblazer in the field of kinase research, with her patented innovations paving the way for new therapeutic strategies in cancer treatment. Her contributions continue to impact the scientific community and enhance our understanding of kinase functions.